No Prescription |
 |
 | ||
|
Reminyl Razadyne |
|
| ||
No Prescription » Prescription Drugs 14 » Reminyl Razadyne Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Reminyl is indicated in the treatment of Mild-to-moderate Alzheimer's disease.Reminyl can delay or even reverse mental decline in some patients with mild to moderate Alzheimer's disease. It is thought to work by boosting levels of the chemical messenger acetylcholine in the brain. (In Alzheimer's disease the cells that produce acetylcholine slowly deteriorate.) Galantamine improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine (ah see til KO leen). People with dementia usually have lower levels of this chemical which is important for the processes of memory thinking and reasoning.Galantamine is used to treat mild to moderate dementia caused by Alzheimer's disease. Buy Reminyl Razadyne and other Prescription Drugs 14 products online at Medstore. 3712
About Reminyl Razadyne: Product Type: Prescription Drugs 14 Reminyl (Razadyne Generic Galantamine) Reminyl (Razadyne Generic Galantamine) Razadyne Generic Galantamine 8mg 28 Tablets Razadyne Generic Galantamine Reminyl
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
